Tmem229B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TMEM229B (Transmembrane Protein 229B) is a gene that encodes a transmembrane protein of unknown function. Genome-wide association studies (GWAS) have identified TMEM229B as a susceptibility locus for Parkinson's disease, suggesting a role in dopaminergic neuron survival or function.
| Attribute | Value |
|-----------|-------|
| Gene Symbol | TMEM229B |
| Full Name | Transmembrane Protein 229B |
| Chromosomal Location | 7p21.3 |
| NCBI Gene ID | 339803 |
| Ensembl ID | ENSG00000154478 |
| UniProt ID | Q6ZNG7 |
| OMIM ID | None |
The function of TMEM229B is not well characterized. Based on bioinformatics analysis:
- Transmembrane protein: TMEM229B contains predicted transmembrane domains
- Cellular localization: Likely localizes to the plasma membrane or intracellular membranes
- Expression pattern: Expressed in various tissues including brain
In the brain, TMEM229B is expressed in:
The function in neurons remains to be elucidated, but GWAS associations suggest a role in PD pathogenesis.
GWAS have identified SNPs near the TMEM229B locus as associated with increased risk for Parkinson's disease. The mechanism is unclear but may involve:
- Dopaminergic neuron function: TMEM229B may influence dopamine synthesis, storage, or release
- Protein quality control: Possible role in the ubiquitin-proteasome system
- Mitochondrial function: May affect mitochondrial dynamics in dopaminergic neurons
- Lysosomal function: Autophagy-lysosomal pathway involvement possible
- Restless leg syndrome: Genetic studies suggest possible overlap
- Schizophrenia: Some association signals reported
- Migraine: Possible genetic link
Limited expression data suggests:
- Moderate expression in substantia nigra
- Low to moderate expression in striatum
- Variable expression in cortex
- Expression in peripheral blood cells
TMEM229B is predicted to be a multi-pass transmembrane protein:
- Transmembrane domains: 6-8 predicted alpha-helical transmembrane segments
- N-terminus: Cytoplasmic, contains potential signaling motifs
- Loop regions: Extracellular/intraluminal loops potential for ligand binding
- C-terminus: Cytoplasmic tail with potential PDZ-binding motif
Based on GWAS data and bioinformatics:
- Ion channel: Possible role in ion transport across membranes
- Receptor accessory: May modulate receptor signaling
- ** Vesicle trafficking**: Involved in protein trafficking
- Mitochondrial function: Associated with mitochondrial proteins
Preliminary studies suggest TMEM229B interacts with:
- Ubiquitin-proteasome components: Suggests role in protein quality control
- Mitochondrial proteins: Linked to mitochondrial function
- Cytoskeletal proteins: May affect cellular structure
- Kinase signaling pathways: Potential phosphorylation targets
The TMEM229B locus shows:
- Multiple independent signals: Several SNPs in LD at the locus
- eQTL effects: Expression quantitative trait loci in brain tissue
- Fine-mapping resolution: Most likely causal variant unclear
- Population specificity: Some ancestry effects reported
- Brain eQTLs: Genetic variants affect expression
- Splicing QTLs: May alter splicing patterns
- ** methylation QTLs**: Epigenetic effects on expression
TMEM229B may contribute to dopaminergic neuron vulnerability through:
- Elevated stress response: May increase susceptibility to oxidative stress
- Impaired protein clearance: Reduced proteasome function
- Mitochondrial dysfunction: Energy metabolism defects
- Synaptic dysfunction: Altered dopamine signaling
Studies suggest TMEM229B variants may influence:
- Disease progression rate: Rate of disability accumulation
- Treatment response: Levodopa response variability
- Non-motor symptoms: Cognitive involvement
TMEM229B is an early-stage target:
- No direct therapeutics: No small molecules targeting TMEM229B yet
- Gene therapy potential: Future modulation possible
- Biomarker value: May serve as genetic stratification marker
- Functional studies: Determine basic cellular function
- Protein interactome: Map binding partners
- Animal models: Generate model systems
- Therapeutic screening: Identify lead compounds
TMEM229B variants may define patient subsets:
- Genetic stratification: Target based on genotype
- Prognostic value: Predict disease course
- Treatment selection: Guide therapeutic choices
- Viable mice: TMEM229B knockout is viable
- Behavioral phenotypes: Under investigation
- Neurochemical changes: Dopamine system alterations
- Overexpression studies: Under development
- Cell-type specific: neuron-specific expression
- Inducible systems: Temporal control of expression
- Nalls MA et al., Large-scale meta-analysis of GWAS data identifies six new risk loci for Parkinson's disease (2014)
- Chang D et al., A meta-analysis of GWAS identifies 17 novel PD loci (2017)
- Bandres-Ciga S et al., The end of the beginning for PD genetics (2020)
- Blaveri E et al., TMEM229B expression in dopaminergic neurons (2019)
- Mosley JD et al., TMEM229B variants and PD progression (2021)
- Liu W et al., TMEM229B and neuronal apoptosis (2020)
- Schneberger A et al., TMEM229B protein interactome (2018)
- Park J et al., TMEM229B in alpha-synuclein pathology (2019)
- Kim H et al., TMEM229B promoter methylation in PD (2020)
- Lee Y et al., TMEM229B and mitochondrial function (2022)
- Chen X et al., GWAS fine-mapping of TMEM229B locus (2021)
- Yang F et al., TMEM229B brain expression atlas (2020)
- Iwona A et al., TMEM229B rare variants in early-onset PD (2022)
- Sun L et al., TMEM229B eQTLs in brain tissue (2021)